Axol Bioscience key facts
as of Oct 2026- Operator of a biotechnology company intended for medical research, disease modeling, and drug development.
- Axol Bioscience is valued at approximately $128.1M as of Oct 2026 (last reported valuation).
- It has raised $19.9M; the latest was Later Stage VC ($2.8M) in Jan 2026.
- Notable investors include Scottish Enterprise, SyndicateRoom, Cambridge Angels, Amadeus Capital Partners, Meltwind Advisory — 14 tracked in total.
- Status: Privately Held (backing).
Axol Bioscience's last reported valuation, Aug 2017. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch Axol Bioscience: the Monday email on marks, rounds and moves
Axol Bioscience funding rounds
No funding rounds for Axol Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Axol Bioscience
14+Axol Bioscience valuation
Axol Bioscience's last reported valuation was $128 million in Aug 2017. No priced round, secondary trade or fund mark has surfaced since.
Axol Bioscience investors
14 investors are on record for Axol Bioscience, including Scottish Enterprise, SyndicateRoom, Cambridge Angels and Amadeus Capital Partners.
About Axol Bioscience
Operator of a biotechnology company intended for medical research, disease modeling, and drug development. The company generates stem cells from blood and tissue cells, extracted from healthy and diseased patients, to develop the best human cell biology research tools, which can advance medical research and drug discovery for many of the world's biggest and best-known pharma companies and research institutions, enabling researchers to develop treatments based on stem cell research.
- Sector
- Healthcare
- HQ
- Roslin, United Kingdom
- Founded
- 2013
- Employees
- 46
- Website
- axolbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.